TCTR20211224002招募中3 期
Efficacy and safety of Andrographis paniculata extract for the treatment of asymptomatic or mild-symptoms COVID-19 patients: A double-blinded, randomized-control trial
Health System Research Institute0 个研究点目标入组 736 人开始时间: 2021年12月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 736
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •1. Male or female aged 18-60 yrs.
- •2. Confirmed COVID-19 infection with RT-PCR within 72 hrs.
- •3. No clinical or mild symptoms with WHO clinical progression scale not more than 2 and Oxygen saturation more than 96% and no desaturation after performed a minute of Sit-to-stand test and chest x-ray does not illustrated evidence of pneumonia which confirmed by at least 2 of three chest-internal medicine specialized physician or radiologist doctor.
- •4. Respiratory rate not over than 20 times per min.
- •5. No underlying or uncontrollable underlying disease during last 6 months.
- •6. Agree to participate in this trial.
排除标准
- •1. Has history of Andrographis paniculata extract or capsules.
- •2. Has clinical severity more than two of WHO clinical progression scale
- •3. Has history of taking one to more of chloroquine, hydroxychloroquine, ivermectin, interferon or antibiotics during the last seven days
- •4. Has history of taking any herbs or Andrographis paniculata extract or capsules unless the taking dose is less than 30 percent of our recommend doses or 60 mg/day
- •5. Has history of taking at least one or more of corticosteroid drugs, chemotherapy drugs or radiotherapy during the last 6 months.
- •6. Has history of taking Clopidogrel,warfarin, statins, amlodiprine, clozapine, and Phenytoin.
- •7. Pregnant or breast-feeding woman.
- •8. High risk groups
- •8.1 BMI equal or more than 30 kg/m2
- •8.3 CKD stage 3 and up
- •8.4 Cardiovascular disease
- •8.5 Stroke
- •8.6 Uncontrolled diabetes mellitus
- •8.7 Cirrhosis or hepatitis which AST or ALT elevated more than 3 times of ULN.
- •8.8 Lymphocyte is less than 1,000 Cell/mm3)
- •8.9 Cancer patients.
研究者
相似试验
已完成
1 期
Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trialTCTR20210708001Thai Traditional Medicine Knowlegde funding63
已完成
3 期
The efficacy and safety of Andrographis paniculata extract for the treatment of acute nonspecific upper respiratory tract infections: a randomized double-blind placebo controlled trialAcute nonspecific upper respiratory tract infections with one or more symptoms such as fever,sore throat,nasal congestion,dry infrequent cough and had modified Centor Score of 2 or less.Andrographis paniculataandrographolideacute nonspecific upper respiratory tract infectionspharyngitiscommon coldTCTR20170329002Department of Thai Traditional and Alternative Medicine829
尚未招募
4 期
A clinical study to understand the combined effects of Andrographis & metformin, in comparison to metformin alone treatment on glycemic control in type 2 diabetes patientsCTRI/2019/11/021977Dr Anand Kumar Maurya
已完成
2 期
Comparison efficacy and safety of Andrographis paniculata extract capsules and placebo in COVID-19 patients: Double blind randomized control trialCOVID-19 patient with asymptomatic and mild symptomatic. Progression score between 0-3. (Green color)COVID-19AndrographolideTCTR20210809004Thammasat university186
已完成
2 期
Efficacy of Andrographis paniculata extract Combined with Favipiravir Treatment to Prevent Disease Progression in mild to moderate COVID-19 Patients: A Double-blind, Randomized, Placebo-Controlled StudyMild to moderate COVID-19andrographolides, COVID-19, SARS-CoV-2, andrographis panniculata, favipiravirTCTR20210609001Chulabhorn Royal Academy146